Literature DB >> 26154007

Public biotech in 2014--the numbers.

Chris Morrison, Riku Lähteenmäki.   

Abstract

Mesh：

Year:  2015        PMID： 26154007     DOI： 10.1038/nbt.3278

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Improvement and decline in vision with gene therapy in childhood blindness.

Authors:  Samuel G Jacobson; Artur V Cideciyan; Alejandro J Roman; Alexander Sumaroka; Sharon B Schwartz; Elise Heon; William W Hauswirth
Journal:  N Engl J Med       Date:  2015-05-03       Impact factor: 91.245

2.  The special case of gene therapy pricing.

Authors:  Troyen A Brennan; James M Wilson
Journal:  Nat Biotechnol       Date:  2014-09       Impact factor: 54.908
  2 in total
  4 in total

1.  Second-quarter biotech job picture.

Authors:  Michael Francisco
Journal:  Nat Biotechnol       Date:  2016-08-09       Impact factor: 54.908

2.  Estimating the biotech sector's contribution to the US economy.

Authors:  Robert Carlson
Journal:  Nat Biotechnol       Date:  2016-03       Impact factor: 54.908

3.  Rethinking Value in the Bio-economy: Finance, Assetization, and the Management of Value.

Authors:  Kean Birch
Journal:  Sci Technol Human Values       Date:  2016-08-10

4.  Comparing long-term value creation after biotech and non-biotech IPOs, 1997-2016.

Authors:  Ekaterina Galkina Cleary; Laura M McNamee; Skyler de Boer; Jeremy Holden; Liam Fitzgerald; Fred D Ledley
Journal:  PLoS One       Date:  2021-01-06       Impact factor: 3.240
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.